In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
In this Consultant360 interview, Brian Bergmark, MD explains how olezarsen, an RNA-targeted therapy targeting APOC3, may help address residual cardiovascular risk in patients with moderate...
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
At the 2025 American Society of Hematology (ASH) Annual Meeting, Brady Stein, MD, chaired a session introducing the forthcoming ASH Clinical Practice Guidelines on Myelofibrosis—the first ASH-supported...
In a recent presentation at Practical Updates in Primary Care, Joel M. Gelfand, MD, provided an overview of psoriasis care for primary care providers alongside co-presenter Annie Truss, MD. In this...
